Considering its significant role in epigenetic regulation, SETD2 expression levels exhibit considerable heterogeneity across different tumor types, and its dysregulation has been associated with distinct prognostic outcomes such as increased tumor aggressiveness, metastatic potential, and resistance to therapy. Here, SETD2 is linked to neoplasm.